Zhiying You
Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 19 | 2025 | 640 | 1.880 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 12 | 2026 | 244 | 1.630 |
Why?
| | Glomerular Filtration Rate | 15 | 2026 | 745 | 0.690 |
Why?
| | Acute Kidney Injury | 7 | 2023 | 866 | 0.640 |
Why?
| | Kidney | 12 | 2026 | 1498 | 0.620 |
Why?
| | Endothelium, Vascular | 6 | 2021 | 952 | 0.560 |
Why?
| | Vascular Stiffness | 6 | 2025 | 488 | 0.530 |
Why?
| | Kidney Failure, Chronic | 6 | 2023 | 589 | 0.520 |
Why?
| | Cognitive Dysfunction | 5 | 2025 | 481 | 0.500 |
Why?
| | Cognition | 6 | 2025 | 1292 | 0.450 |
Why?
| | Uric Acid | 3 | 2021 | 167 | 0.420 |
Why?
| | Sodium Bicarbonate | 3 | 2025 | 48 | 0.400 |
Why?
| | Fibroblast Growth Factors | 4 | 2020 | 187 | 0.380 |
Why?
| | Hypertension | 5 | 2021 | 1272 | 0.350 |
Why?
| | Kidney Diseases | 3 | 2022 | 428 | 0.340 |
Why?
| | Blood Pressure | 5 | 2021 | 1765 | 0.340 |
Why?
| | Acidosis | 2 | 2025 | 105 | 0.340 |
Why?
| | Double-Blind Method | 11 | 2025 | 2070 | 0.320 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2025 | 449 | 0.320 |
Why?
| | Blood Vessels | 2 | 2024 | 164 | 0.320 |
Why?
| | Complement System Proteins | 4 | 2022 | 326 | 0.310 |
Why?
| | Complement Factor B | 2 | 2023 | 106 | 0.310 |
Why?
| | Cardiovascular Diseases | 4 | 2023 | 2219 | 0.300 |
Why?
| | Metformin | 2 | 2024 | 328 | 0.290 |
Why?
| | Brachial Artery | 3 | 2020 | 207 | 0.290 |
Why?
| | Renal Circulation | 2 | 2026 | 75 | 0.280 |
Why?
| | Biomarkers | 12 | 2025 | 4340 | 0.280 |
Why?
| | Pravastatin | 2 | 2025 | 45 | 0.270 |
Why?
| | Chronic Kidney Disease-Mineral and Bone Disorder | 2 | 2018 | 14 | 0.270 |
Why?
| | Oxidative Stress | 3 | 2025 | 1369 | 0.270 |
Why?
| | Prospective Studies | 16 | 2025 | 8123 | 0.260 |
Why?
| | Creatinine | 2 | 2020 | 511 | 0.260 |
Why?
| | Middle Aged | 31 | 2026 | 36619 | 0.260 |
Why?
| | Sodium | 2 | 2019 | 196 | 0.260 |
Why?
| | Vasodilation | 3 | 2020 | 519 | 0.250 |
Why?
| | Phosphates | 2 | 2024 | 175 | 0.230 |
Why?
| | Male | 40 | 2026 | 73396 | 0.230 |
Why?
| | Endothelial Cells | 3 | 2021 | 876 | 0.230 |
Why?
| | Critical Illness | 3 | 2023 | 908 | 0.230 |
Why?
| | Aged | 25 | 2025 | 26432 | 0.230 |
Why?
| | Humans | 55 | 2026 | 146342 | 0.220 |
Why?
| | Kidney Transplantation | 4 | 2019 | 735 | 0.220 |
Why?
| | Female | 39 | 2026 | 79499 | 0.220 |
Why?
| | Cerebrovascular Circulation | 2 | 2025 | 293 | 0.210 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 2 | 2024 | 42 | 0.210 |
Why?
| | Lanthanum | 1 | 2024 | 13 | 0.210 |
Why?
| | Renal Dialysis | 2 | 2019 | 461 | 0.200 |
Why?
| | Bicarbonates | 2 | 2023 | 44 | 0.200 |
Why?
| | Kidney Tubules | 1 | 2024 | 117 | 0.200 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2024 | 147 | 0.190 |
Why?
| | Disease Progression | 8 | 2025 | 2867 | 0.190 |
Why?
| | Overweight | 2 | 2026 | 614 | 0.190 |
Why?
| | Caloric Restriction | 1 | 2024 | 133 | 0.190 |
Why?
| | Pregnancy Complications | 2 | 2018 | 609 | 0.180 |
Why?
| | Ferric Compounds | 1 | 2022 | 55 | 0.180 |
Why?
| | Cardiovascular System | 1 | 2023 | 137 | 0.170 |
Why?
| | Sucrose | 1 | 2022 | 113 | 0.170 |
Why?
| | Adult | 22 | 2026 | 41087 | 0.170 |
Why?
| | Complement Pathway, Classical | 1 | 2021 | 18 | 0.170 |
Why?
| | Nephrosis, Lipoid | 1 | 2021 | 11 | 0.170 |
Why?
| | Complement Factor H | 1 | 2022 | 81 | 0.170 |
Why?
| | Curcumin | 1 | 2021 | 29 | 0.170 |
Why?
| | Breathing Exercises | 1 | 2021 | 21 | 0.170 |
Why?
| | Inhalation | 1 | 2021 | 28 | 0.170 |
Why?
| | Respiratory Muscles | 1 | 2021 | 36 | 0.170 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2021 | 43 | 0.170 |
Why?
| | Nephrotic Syndrome | 1 | 2021 | 44 | 0.170 |
Why?
| | Dementia | 1 | 2025 | 324 | 0.170 |
Why?
| | Cardiolipins | 1 | 2021 | 83 | 0.160 |
Why?
| | Peritoneal Dialysis | 1 | 2022 | 100 | 0.160 |
Why?
| | Kidney Glomerulus | 1 | 2021 | 129 | 0.160 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2021 | 106 | 0.160 |
Why?
| | Allopurinol | 2 | 2018 | 70 | 0.160 |
Why?
| | Immunoglobulin M | 1 | 2021 | 284 | 0.150 |
Why?
| | Bone Diseases | 1 | 2020 | 60 | 0.150 |
Why?
| | Lipocalins | 1 | 2019 | 35 | 0.150 |
Why?
| | Pilot Projects | 5 | 2025 | 1888 | 0.150 |
Why?
| | Antigen-Antibody Complex | 1 | 2019 | 70 | 0.150 |
Why?
| | Complement C3d | 1 | 2019 | 67 | 0.150 |
Why?
| | Epitopes | 1 | 2021 | 479 | 0.150 |
Why?
| | Vascular System Injuries | 1 | 2019 | 79 | 0.140 |
Why?
| | Vascular Diseases | 1 | 2021 | 252 | 0.140 |
Why?
| | Spironolactone | 1 | 2019 | 40 | 0.140 |
Why?
| | Obesity | 2 | 2026 | 3131 | 0.140 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2018 | 75 | 0.140 |
Why?
| | Gene Amplification | 1 | 2018 | 116 | 0.140 |
Why?
| | Complement Factor D | 1 | 2018 | 28 | 0.140 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2018 | 71 | 0.140 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2019 | 534 | 0.140 |
Why?
| | Renal Replacement Therapy | 1 | 2019 | 102 | 0.140 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 69 | 0.140 |
Why?
| | Potassium, Dietary | 1 | 2018 | 12 | 0.130 |
Why?
| | Pulse Wave Analysis | 3 | 2025 | 268 | 0.130 |
Why?
| | Regional Blood Flow | 1 | 2020 | 507 | 0.130 |
Why?
| | Fructose | 1 | 2018 | 132 | 0.130 |
Why?
| | Infant, Low Birth Weight | 1 | 2018 | 154 | 0.130 |
Why?
| | Diet | 1 | 2025 | 1273 | 0.130 |
Why?
| | Hyponatremia | 1 | 2018 | 42 | 0.130 |
Why?
| | Sodium, Dietary | 1 | 2018 | 43 | 0.130 |
Why?
| | Infant Mortality | 1 | 2018 | 127 | 0.130 |
Why?
| | Accidental Falls | 1 | 2020 | 227 | 0.130 |
Why?
| | Antibodies | 1 | 2019 | 400 | 0.130 |
Why?
| | Complement Pathway, Alternative | 1 | 2018 | 123 | 0.130 |
Why?
| | Complement Activation | 4 | 2022 | 412 | 0.130 |
Why?
| | Cell-Derived Microparticles | 1 | 2018 | 73 | 0.130 |
Why?
| | Frailty | 1 | 2020 | 208 | 0.130 |
Why?
| | Vascular Calcification | 1 | 2018 | 109 | 0.130 |
Why?
| | Calcitriol | 1 | 2017 | 59 | 0.130 |
Why?
| | Thrombocytopenia | 1 | 2019 | 206 | 0.130 |
Why?
| | Death | 1 | 2018 | 129 | 0.130 |
Why?
| | Propensity Score | 1 | 2019 | 376 | 0.130 |
Why?
| | Cholecalciferol | 1 | 2017 | 60 | 0.120 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2019 | 241 | 0.120 |
Why?
| | Living Donors | 1 | 2018 | 216 | 0.120 |
Why?
| | Contrast Media | 1 | 2019 | 493 | 0.120 |
Why?
| | Hyperuricemia | 1 | 2016 | 47 | 0.120 |
Why?
| | Nitric Oxide | 1 | 2021 | 883 | 0.120 |
Why?
| | Cross-Sectional Studies | 7 | 2026 | 5899 | 0.120 |
Why?
| | Pre-Eclampsia | 1 | 2018 | 206 | 0.120 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2018 | 269 | 0.110 |
Why?
| | Risk Factors | 8 | 2025 | 10921 | 0.110 |
Why?
| | Skin Neoplasms | 1 | 2022 | 806 | 0.110 |
Why?
| | Recombinant Fusion Proteins | 1 | 2017 | 663 | 0.110 |
Why?
| | Peripheral Arterial Disease | 1 | 2021 | 507 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2023 | 1763 | 0.100 |
Why?
| | Myocardial Infarction | 1 | 2022 | 1215 | 0.100 |
Why?
| | Glioma | 1 | 2018 | 425 | 0.100 |
Why?
| | Interleukin-1 | 1 | 2017 | 960 | 0.100 |
Why?
| | Dietary Supplements | 1 | 2017 | 587 | 0.090 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 823 | 0.090 |
Why?
| | Longitudinal Studies | 5 | 2020 | 3017 | 0.090 |
Why?
| | Follow-Up Studies | 6 | 2019 | 5439 | 0.090 |
Why?
| | Lipocalin-2 | 2 | 2024 | 80 | 0.090 |
Why?
| | Case-Control Studies | 4 | 2021 | 3647 | 0.090 |
Why?
| | Time Factors | 5 | 2021 | 7109 | 0.080 |
Why?
| | Sex Factors | 3 | 2025 | 2107 | 0.080 |
Why?
| | Organ Size | 2 | 2025 | 465 | 0.080 |
Why?
| | Tooth Loss | 1 | 2011 | 27 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2017 | 733 | 0.080 |
Why?
| | Human Growth Hormone | 1 | 2011 | 46 | 0.080 |
Why?
| | Growth Disorders | 1 | 2011 | 89 | 0.080 |
Why?
| | Vitamin D | 3 | 2018 | 402 | 0.080 |
Why?
| | Severity of Illness Index | 4 | 2020 | 2921 | 0.080 |
Why?
| | Liver | 1 | 2018 | 1864 | 0.080 |
Why?
| | Risk Assessment | 4 | 2021 | 3712 | 0.070 |
Why?
| | Young Adult | 6 | 2023 | 14330 | 0.070 |
Why?
| | Brain Neoplasms | 1 | 2018 | 1325 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2017 | 1107 | 0.070 |
Why?
| | Aged, 80 and over | 5 | 2025 | 8391 | 0.070 |
Why?
| | Geography | 1 | 2008 | 187 | 0.070 |
Why?
| | United States | 7 | 2024 | 16136 | 0.070 |
Why?
| | Nutritional Status | 2 | 2022 | 346 | 0.070 |
Why?
| | Phosphorus | 2 | 2022 | 89 | 0.060 |
Why?
| | Parathyroid Hormone | 2 | 2018 | 118 | 0.060 |
Why?
| | Prognosis | 3 | 2021 | 4351 | 0.060 |
Why?
| | Independent Living | 2 | 2018 | 114 | 0.060 |
Why?
| | Mice | 5 | 2022 | 18297 | 0.060 |
Why?
| | Body Mass Index | 3 | 2026 | 2458 | 0.060 |
Why?
| | Treatment Outcome | 4 | 2025 | 11821 | 0.060 |
Why?
| | Self Report | 1 | 2011 | 870 | 0.060 |
Why?
| | Neuropsychological Tests | 2 | 2024 | 1149 | 0.060 |
Why?
| | Coronary Disease | 1 | 2008 | 380 | 0.060 |
Why?
| | Inflammation Mediators | 2 | 2019 | 508 | 0.060 |
Why?
| | Middle Cerebral Artery | 1 | 2025 | 57 | 0.060 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2025 | 48 | 0.060 |
Why?
| | Brain | 1 | 2018 | 2991 | 0.060 |
Why?
| | Aspirin | 1 | 2008 | 405 | 0.050 |
Why?
| | Health Status Disparities | 1 | 2008 | 322 | 0.050 |
Why?
| | Child | 5 | 2023 | 22693 | 0.050 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2024 | 18 | 0.050 |
Why?
| | Vegetables | 1 | 2025 | 159 | 0.050 |
Why?
| | Pregnancy Outcome | 2 | 2018 | 503 | 0.050 |
Why?
| | Chemokine CCL2 | 1 | 2024 | 112 | 0.050 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2008 | 499 | 0.050 |
Why?
| | Intensive Care Units | 2 | 2021 | 925 | 0.050 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2024 | 80 | 0.050 |
Why?
| | Animals | 6 | 2022 | 38107 | 0.050 |
Why?
| | Magnetic Resonance Angiography | 1 | 2025 | 249 | 0.050 |
Why?
| | Incidence | 2 | 2021 | 2936 | 0.050 |
Why?
| | Plant Proteins | 1 | 2023 | 110 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2021 | 4118 | 0.050 |
Why?
| | Stroke | 2 | 2011 | 1287 | 0.050 |
Why?
| | Patched-1 Receptor | 1 | 2022 | 14 | 0.050 |
Why?
| | Hyperphosphatemia | 1 | 2022 | 15 | 0.050 |
Why?
| | Hypoalbuminemia | 1 | 2022 | 26 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2023 | 270 | 0.040 |
Why?
| | Serum Albumin | 1 | 2022 | 147 | 0.040 |
Why?
| | Gonadal Steroid Hormones | 1 | 2022 | 143 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2021 | 181 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2022 | 321 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 194 | 0.040 |
Why?
| | Cohort Studies | 3 | 2018 | 6077 | 0.040 |
Why?
| | Drug Combinations | 1 | 2022 | 400 | 0.040 |
Why?
| | Minerals | 1 | 2020 | 48 | 0.040 |
Why?
| | Prevalence | 2 | 2018 | 2861 | 0.040 |
Why?
| | Mice, Inbred MRL lpr | 1 | 2019 | 37 | 0.040 |
Why?
| | Lymphocytes | 1 | 2022 | 379 | 0.040 |
Why?
| | Acute-Phase Proteins | 1 | 2019 | 66 | 0.040 |
Why?
| | Matched-Pair Analysis | 1 | 2019 | 38 | 0.040 |
Why?
| | Ultraviolet Rays | 1 | 2022 | 376 | 0.040 |
Why?
| | Colorado | 2 | 2021 | 4595 | 0.040 |
Why?
| | Monocytes | 1 | 2022 | 538 | 0.040 |
Why?
| | Allografts | 1 | 2019 | 151 | 0.040 |
Why?
| | Complement C4a | 1 | 2018 | 9 | 0.030 |
Why?
| | Testosterone | 1 | 2022 | 419 | 0.030 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2019 | 175 | 0.030 |
Why?
| | Half-Life | 1 | 2018 | 157 | 0.030 |
Why?
| | Hepatocytes | 1 | 2019 | 224 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2019 | 416 | 0.030 |
Why?
| | Biological Availability | 1 | 2018 | 146 | 0.030 |
Why?
| | Complement Membrane Attack Complex | 1 | 2018 | 38 | 0.030 |
Why?
| | Complement C5a | 1 | 2018 | 54 | 0.030 |
Why?
| | Clone Cells | 1 | 2018 | 259 | 0.030 |
Why?
| | Chromosome Aberrations | 1 | 2018 | 167 | 0.030 |
Why?
| | Area Under Curve | 1 | 2018 | 335 | 0.030 |
Why?
| | Fathers | 1 | 2018 | 53 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2023 | 801 | 0.030 |
Why?
| | TRPP Cation Channels | 1 | 2018 | 76 | 0.030 |
Why?
| | Ligands | 1 | 2019 | 678 | 0.030 |
Why?
| | Healthy Aging | 1 | 2018 | 44 | 0.030 |
Why?
| | Rats, Wistar | 1 | 2018 | 451 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 417 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2021 | 1135 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2021 | 829 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 617 | 0.030 |
Why?
| | Biopsy | 1 | 2019 | 1075 | 0.030 |
Why?
| | Up-Regulation | 1 | 2019 | 841 | 0.030 |
Why?
| | Graft Rejection | 1 | 2019 | 516 | 0.030 |
Why?
| | Congenital Abnormalities | 1 | 2017 | 108 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2018 | 615 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2018 | 6460 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 872 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1378 | 0.030 |
Why?
| | Adolescent | 3 | 2021 | 22557 | 0.030 |
Why?
| | Waiting Lists | 1 | 2017 | 251 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2019 | 784 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 970 | 0.030 |
Why?
| | Neuroimaging | 1 | 2018 | 307 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2019 | 901 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2018 | 3926 | 0.030 |
Why?
| | Pregnancy | 2 | 2018 | 7230 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2024 | 1412 | 0.030 |
Why?
| | Autoimmunity | 1 | 2019 | 925 | 0.020 |
Why?
| | Protein Binding | 1 | 2019 | 2244 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2113 | 0.020 |
Why?
| | Glucose | 1 | 2018 | 1053 | 0.020 |
Why?
| | Survival Rate | 1 | 2018 | 2092 | 0.020 |
Why?
| | Recovery of Function | 1 | 2017 | 725 | 0.020 |
Why?
| | Premature Birth | 1 | 2017 | 390 | 0.020 |
Why?
| | Intestinal Mucosa | 1 | 2018 | 666 | 0.020 |
Why?
| | Genotype | 1 | 2018 | 1879 | 0.020 |
Why?
| | Age Factors | 1 | 2020 | 3347 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2019 | 3125 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2019 | 1512 | 0.020 |
Why?
| | Autoantibodies | 1 | 2019 | 1500 | 0.020 |
Why?
| | Cytokines | 1 | 2019 | 2081 | 0.020 |
Why?
| | Mothers | 1 | 2018 | 772 | 0.020 |
Why?
| | Proteomics | 1 | 2018 | 1203 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2020 | 17438 | 0.020 |
Why?
| | Hyperlipidemias | 1 | 2011 | 120 | 0.020 |
Why?
| | Rats | 1 | 2018 | 5586 | 0.020 |
Why?
| | Income | 1 | 2011 | 206 | 0.020 |
Why?
| | Mental Recall | 1 | 2011 | 226 | 0.020 |
Why?
| | Social Class | 1 | 2011 | 260 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4580 | 0.020 |
Why?
| | Educational Status | 1 | 2011 | 466 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2011 | 429 | 0.020 |
Why?
| | Blood Glucose | 1 | 2018 | 2360 | 0.020 |
Why?
| | Learning | 1 | 2011 | 446 | 0.020 |
Why?
| | Calcium | 1 | 2011 | 1181 | 0.010 |
Why?
| | Infant | 1 | 2018 | 10114 | 0.010 |
Why?
| | Smoking | 1 | 2011 | 1486 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2011 | 1101 | 0.010 |
Why?
| | Depression | 1 | 2011 | 1575 | 0.010 |
Why?
|
|
You's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|